Anvisa bans commercialization and use of Acanne cannabis products due to lack of valid authorization
The measure covers the entire line of oils, gummies, sprays, and topical items from the Associação Canábica Nordeste, cited for operating without registration and at an unverified location.
The Brazilian Health Regulatory Agency (Anvisa) has determined the total ban on the manufacturing, importation, storage, distribution, commercialization, and use of all cannabis-based products linked to the Associação Canábica Nordeste (Acanne). The decision was formalized through Resolution RE No. 3,055, published in the Official Gazette of the Union.
According to Anvisa's inspection, the measure covers all batches and presentations of the association due to key irregularities:
- Absence of a valid Operating Authorization (AFE) with the health authority;
- Operation in an uncertain and unknown location, unconfirmed by inspection teams;
- Indications of commercialization of cannabis products without the registration or health authorization required by Brazilian regulations.
Variety of items sold
The agency's investigation identified that the association offered a broad product line through digital sales channels, displaying prices and customer service options. Among the items sold were formulations in different cannabinoid concentrations — isolates or Full Spectrum —, as well as varied formats:
- CBD oils with different concentrations (such as CBD Broad 1500 mg, CBD Full 1500 mg, CBD Full 3000 mg, and CBD ISO 6000 mg);
- Combination formulations (CBD THC Full);
- Edibles and alternative-use products, such as gummies (Gummies CBD 750 mg and Gummies D9THC 300 mg);
- CBD Spray 30 mg presentations and topical products (Get Roll-on CBD 1500 mg).
Anvisa emphasizes that the existence of structured online sales pages and catalog offerings do not substitute for nor prove the legal status of an establishment or its products before health surveillance.
Impact on the regulated market
The ruling reinforces the regulatory body's strict oversight of the medical cannabis sector in Brazil, highlighting that patient access must be strictly aligned with requirements for composition control, traceability, manufacturing quality, and technical responsibility established by the current regulatory framework.